(NASDAQ: AFFX) today announced the expansion of its license agreement with Siemens Healthcare Diagnostics for the company’s branched DNA (bDNA) technology whereby Affymetrix is the exclusive licensee ...
Global genetic products developer and manufacturer Affymetrix, Inc. (AFFX) recently announced a world-wide collaboration with Leica Microsystems, a leading manufacturer of microscopes and other ...
SANTA CLARA, Calif. & SAN DIEGO--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ:AFFX) and Reveal Biosciences LLC, an advanced tissue technologies company, today announced a partnership agreement through ...
Technology combines ScreenCell’s isolation devices with Affymetrix’ QuantiGene ViewRNA assay. Affymetrix signed a worldwide distribution agreement for ScreenCell’s isolation devices and dilution ...
Partnership will expand use of assay into pathology and cancer research markets. Affymetrix and the Massachusetts General Hospital (MGH) inked a collaboration and licensing agreement to co-develop ...
Affymetrix Inc., a pioneer in creating breakthrough tools that are driving the genomic revolution, and Leica Microsystems, a world leader in microscopes and scientific instruments, has signed a ...
Combination of ScreenCell's isolation devices and Affymetrix' QuantiGene(R) ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs ...
Affymetrix Inc. and Reveal Biosciences LLC, an advanced tissue technologies company, announced a partnership agreement through which Reveal will use Affymetrix ViewRNA ISH products for tissue samples ...
Affymetrix, Inc. and ScreenCell have announced the signing of a worldwide distribution agreement for ScreenCell’s isolation devices and dilution buffers, designed for the collection of Circulating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results